Tridihexethyl

Summary

Tridihexethyl (CHEMBL1201354) is an approved small-molecule anti-ulcer drug (ATC A03AB08); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A03AB08
• Indications: 1 condition
• Chemistry: 318.5 Da · C21H36NO+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201354
Name	Tridihexethyl
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	20299
ChEBI	CHEBI:9701
ATC	A03AB08
Molecular formula	C21H36NO+
Molecular weight	318.5
InChIKey	NPRHVSBSZMAEIN-UHFFFAOYSA-N

SMILES: CC[N+](CC)(CC)CCC(C1CCCCC1)(C2=CC=CC=C2)O

IUPAC name: (3-cyclohexyl-3-hydroxy-3-phenylpropyl)-triethylazanium

Pharmacological roles (ChEBI): anti-ulcer drug, muscarinic antagonist, antispasmodic drug.

Also known as: Tridihexethyl, Tridihexethyl cation, Tridihexethyl ion, SID11112922, TRIDIHEXETHYL, tridihexethyl

Parent form; salt/anhydrous children: CHEMBL1200771, CHEMBL2107686

Patent coverage: 203 distinct patent families (653 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Voltage-gated inwardly rectifying potassium channel KCNH2, Cytochrome P450 2D6.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 5 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CHRM1	8.08	AC50	8.3	nM	CHEMBL_ACT_25210337
CHRM2	7.82	AC50	15.3	nM	CHEMBL_ACT_25195882
CYP2D6	7.7	Potency	20	nM	CHEMBL_ACT_5002491
CYP2D6	7.7	AC50	19.95	nM	CHEMBL_ACT_6054543

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).